NEWS.

Adding the amylin agonist eloralintide to tirzepatide produced 23.3 percent weight loss over 48 weeks against 14.8 percent for tirzepatide alone, Lilly reported at EASD. The extra 8.5 points came with adverse-event discontinuation of up to 27.0 percent across the combination arms versus 2.9 percent on tirzepatide by itself. Phase 3 will test a reformulated, co-formulated version with an adjusted dose-escalation, not the two-injection regimen from this Phase 2b.

Eli Lilly's triple agonist cut weight 20.8 percent over 80 weeks in adults with obesity and type 2 diabetes in TRIUMPH-2, published in The Lancet and presented at EASD. That is below the 28.3 percent the same drug hit at the same dose in obesity without diabetes, and the 20.8 is the efficacy estimand. The treatment-regimen number, which counts dropouts, is 18.8. Dysesthesia climbed with dose to 7.3 percent. FDA filing is planned for Q1 2027.

A Lilly-authored US claims analysis found tirzepatide starters were more adherent and more likely to reach strict blood-sugar and weight goals than semaglutide starters, at a lower cost per responder. The eye-popping three-to-one gaps sit at the strictest targets, where the tiny denominator, not the molecule, does most of the work.

A regulator-mandated Nordic registry study of 97,464 semaglutide users found no rise in pancreatic cancer versus older diabetes drugs. Mean follow-up was 1.4 to 1.85 years, far short of the disease's usual latency, so the null speaks to short-term risk and stays silent on the long term.

A Gothenburg lab flattened nicotine-driven dopamine, place preference, and relapse behavior in male mice with the dual GIP/GLP-1 drug, but the report gives directions without magnitudes and the human evidence remains thin.

A single-center study of 180 obese women found their own GLP-1 fell as endometrial tissue turned malignant, posting an AUC of 0.94 that a cross-sectional design cannot turn into cause.

A single-arm pilot paired a checkpoint drug with targeted radiation in 26 neuroendocrine cancer patients and saw a 35 percent response rate. With no radiation-only group to compare against, and severe side effects in over half of patients, the study cannot show the immune drug added anything.

A TriNetX cohort reports that GLP-1 drugs lowered every measured outcome after liver transplant, including a surgical clot and immune rejection the drugs have no plausible way to prevent. That uniform benefit is the fingerprint of confounding, not proof the drugs save lives.

A six-month study of 539 people with type 2 diabetes found that pairing dapagliflozin with once-weekly semaglutide tracked with a lower heart failure rate but worse blood sugar control. The retrospective, single-center design means the trade-off is an association, not proof the combination caused either result.

A European committee wants to give the peptide-drug conjugate Pepaxti to myeloma patients earlier in their care, based on the same Phase 3 trial that led the FDA to pull the drug from the US market in 2024.

The boxed warning on every GLP-1 drug traces to thyroid C-cell tumors in rats and mice. A new weight-of-evidence analysis in Regulatory Toxicology and Pharmacology runs seven approved GLP-1 receptor agonists through the ICH S1B(R1) framework and concludes the rodent tumors arise through a mechanism largely absent in humans, where thyroid C-cells carry very few GLP-1 receptors, so further two-year rat bioassays add no value. It is an argument to test less, not new human data, authored by a consulting firm with a Novartis co-author, and the boxed warning plus the MTC and MEN2 contraindication still stand.

Novo Nordisk agreed on September 25 to pay Nanexa up to 1.165 billion euros for PharmaShell, an atom-thin coating that meters a drug particle's release so an injection can last a month or a quarter instead of a week. The target it names is not a new receptor but a calendar. It signals where the obesity race has moved: the molecules are settled, and the gains left are in getting people to stay on them.

Roche's September 22 topline for enicepatide (the former CT-388) is impressive on its face: a 2.65-point HbA1c fall and 15.5 percent weight loss over 48 weeks in 447 adults with type 2 diabetes. Every headline number is measured from each patient's own baseline. The one figure the release withholds is what the placebo arm did over the same year, which is the only comparison that tells you what the drug actually added.

A Clinical Therapeutics review gathers 31 case reports and 232 FDA filings of suspected liver injury from GLP-1 drugs, a class developed partly to treat fatty-liver disease, and finds the liver is not listed as a safety concern on their labels.

A Beijing group rebuilt the tip of a fusion-inhibitor lipopeptide by adding one amino acid, restoring potency against the resistant HIV mutants that defeat the class and clearing virus below detection in mice and macaques.